EU regulator recommends use of Pfizer’s gene therapy for rare bleeding disorder

(Reuters) – The European Medicines Agency has recommended the use of Pfizer’s gene therapy for a rare bleeding disorder called hemophilia B, which typically requires regular infusions of a blood-clotting protein, the regulator said on Friday.

(Reporting by Sriparna Roy and Puyaan Singh in Bengaluru; Editing by Shailesh Kuber)